ErbB3, a member of the ErbB family of receptor tyrosine kinases, is a potent activator of phosphatidyl inositol-3 kinase (PI3K) and mTOR signaling, driving tumor cell survival and therapeutic resistance in breast cancers. In luminal breast cancers, ErbB3 upregulation following treatment with the anti-estrogen fulvestrant enhances PI3K/mTOR-mediated cell survival. However, the mechanism by which ErbB3 is upregulated in fulvestrant-treated cells is unknown. We found that ErbB3 protein levels and cell surface presentation were increased following fulvestrant treatment, focusing our attention on proteins that regulate ErbB3 at the cell surface, including Nrdp1, NEDD4, and LRIG1. Among these, only LRIG1 correlated positively with ERα, but inversely with ErbB3 in clinical breast cancer datasets. LRIG1, an estrogen-inducible ErbB down-regulator, was decreased in a panel of fulvestrant-treated luminal breast cancer cells. Ectopic LRIG1 expression from an estrogen-independent promoter uncoupled LRIG1 from estrogen regulation, thus sustaining LRIG1 and maintaining low ErbB3 levels in fulvestrant-treated cells. An LRIG1 mutant lacking the ErbB3 interaction motif was insufficient to down-regulate ErbB3. Importantly, LRIG1 overexpression improved fulvestrant-mediated growth inhibition, while cells expressing the LRIG1 mutant were poorly sensitive to fulvestrant, despite effective ERα downregulation. Consistent with these results, LRIG1 expression correlated positively with increased disease-free survival in anti-estrogen-treated breast cancer patients. These data suggest that ERα-dependent expression of LRIG1 dampens ErbB3 signaling in luminal breast cancer cells, and by blocking ERα activity with fulvestrant, LRIG1 is decreased thus permitting ErbB3 accumulation, enhanced ErbB3 signaling to cell survival pathways, and blunting therapeutic response to fulvestrant.
Introduction
ERBB3, the gene encoding the ErbB receptor tyrosine kinase (RTK) family member ErbB3, is expressed at relatively high levels in breast cancers that are HER2-amplified 1 , and at even higher levels in Luminal A breast cancers 2 , which often express and are dependent on estrogen receptor (ER)-α. Nearly 20% of all Luminal breast tumors exhibit ERBB3 gene copy number gains, causing increased ERBB3 expression, and correlating with decreased disease-free survival 2 . ErbB3 expression is increased further in luminal breast cancers in response to treatment with the selective ERα modulator (SERM) tamoxifen or the selective ERα down-regulator (SERD) fulvestrant 3 -5 , two drugs clinically prescribed to patients with luminal breast cancer. Little is known regarding the role of ErbB3 in luminal breast tumors, largely due to a historical description of ErbB3 as a kinase-impaired heterodimeric partner of EGFR and ErbB2 1 , 6 , 7 . However, increasing evidence suggest that ErbB3 is a key therapeutic target in luminal breast cancers.
Because ErbB3 harbors six phospho-tyrosine motifs that bind to the p85 regulatory subunit of phosphatidyl inositol-3-kinase (PI3K) 1 , 8 -11 , ErbB3 is a potent activator of PI3K signaling 12 . Once active, PI3K generates PIP3, a potent second messenger that recruits PI3K pathway effectors to the plasma membrane (e.g., serine-threonine kinases PDK-1 and Akt), resulting in their activation. Since Akt sits atop a signaling cascade that enhances cell growth and survival 13 , ErbB3 signaling promotes survival of luminal breast cancer cells.
Thus, ErbB3 up-regulation in response to tamoxifen or fulvestrant increases PI3K-Akt signaling within 24 hours of treatment, increasing tumor cell survival and blunting the therapeutic benefit of these endocrine inhibitors 2 , 3 , 5 , 9 . However, combination of endocrine inhibitors with strategies designed to target ErbB3 may be used to circumvent the compensatory up-regulation of ErbB3-PI3K-Akt signaling, and improve luminal breast cancer cell killing. The therapeutic ErbB3 antibody U3-1287, for example, significantly impaired PI3K signaling and survival in fulvestrant-treated luminal breast tumor cells 2 .
The mechanism(s) contributing to ErbB3 up-regulation in response to fulvestrant are poorly understood. However, recent findings demonstrated a 2-fold up-regulation of ERBB3 transcripts in a panel of luminal breast cancer cells 24 h after fulvestrant treatment 2 . Thus, it is likely that additional mechanisms of ErbB3 regulation contribute to enhanced ErbB3 protein expression in fulvestrant-treated luminal breast cancer cells. We found that estrogendependent expression of the ErbB family regulatory factor LRIG1 maintains ErbB3 expression at low levels under basal conditions, and that fulvestrant disrupts ERα-dependent LRIG1 expression, permitting ErbB3 accumulation and survival signaling in fulvestranttreated cells.
Results

The ErbB3 antibody A4 neutralizes fulvestrant-mediated ErbB3 upregulation
Previous studies demonstrate that humanized anti-ErbB3 monoclonal antibody A4 binds the ErbB3 ectodomain and effectively down-regulates ErbB3 in HER2-amplified breast cancer cells through receptor internalization 14 , 15 . However, the utility of A4 in luminal breast cancers has not yet been described. We tested the impact of A4 on ErbB3 protein levels in two luminal breast cancer cell lines, MCF7 and T47D cells. Western analysis confirmed ErbB3 expression in serum-starved MCF7 and T47D cells (Fig. 1A) , but showed that ErbB3 tyrosine phosphorylation at Y1289 was not detected under these conditions. Recombinant heregulin α1 (HRG, 2 ng/ml) induced ErbB3 Y1289 phosphorylation in control cells treated with non-specific human IgG. In contrast, pre-treatment of cells with A4 for 24 h prior to addition of HRG diminished HRG-induced ErbB3 phosphorylation at Y1289 in MCF7 and T47D, and decreased total ErbB3 levels.
Luminal breast cancer cells use ErbB3 up-regulation in response to ERα targeting to increase tumor cell growth and survival 2 , 8 , 9 . Therefore, we tested the ability of antibody A4 To determine the impact of A4 on growth of luminal breast cancer cells, we treated 1 X 10 6 MCF7 and T47D cells with A4 for 3 days in media containing 10% serum. Treatment of cells with A4 resulted in a modest but significant decrease in cell number after 3 days of treatment (Fig. 1C) , consistent with previous reports using another ErbB3-specific antibody U3-1287 2 . Treatment of cells with fulvestrant for 3 days decreased cell number. However, the combination of A4 with fulvestrant reduced cell number to a greater extent than either fulvestrant or A4 alone, confirming that ErbB3 up-regulation in fulvestrant-treated cells limits fulvestrant-mediated growth inhibition, and that targeting ErbB3 using the ErbB3 antibody A4 works in combination with fulvestrant to inhibit tumor cell growth through inhibition of ErbB3 expression. We investigated how ErbB3 targeting with antibody A4 affects the formation of fulvestrant-resistant colonies by seeding MCF7 and T47D cells at low density. Cells were cultured for 14 days in the presence of fulvestrant (1μM) or DMSO. Fulvestrant profoundly reduced colony formation in MCF7 and T47D cells (Fig. 1D ). Antibody A4 also decreased colony formation in MCF7 and T47D cells as a single agent. However, the combination of fulvestrant + A4 caused superior growth inhibition as compared to fulvestrant alone or A4 alone. Fig. S1A ). Interestingly, the RPPA score for total ERα (ESR1) protein was significantly down-regulated in tumors with high ErbB3 protein levels ( Fig. 2A) , consistent with the inverse relationship between ERα and ErbB3 protein levels seen in cultured luminal breast cancer cells. Further, phosphorylation of ERα at S118 (which marks ERα transcriptional activity 16 ) was substantially lower in luminal tumors with high ErbB3 protein levels (Supp. Fig. S1B ). In contrast, ERBB3 transcripts were upregulated in 12% (37/324) luminal breast cancer specimens, but primarily in tumors distinct from those with ErbB3 protein up-regulation (Fig. 2B) , demonstrating that ErbB3 mRNA may not predict ErbB3 protein levels in tumors. In contrast to the inverse relation observed between the RPPA scored for ErbB3 and ERα, no relationship was observed between ERα-Ser118 and ERBB3 mRNA levels (Supp. Fig. S1C ), while a positive relationship was seen between ERBB3 mRNA and total ERα protein ( Fig. 2A ). These data suggest that ErbB3 protein and ERRB3 mRNA correlate with ERα in distinct ways. This observation is consistent with the idea that ErbB3 protein expression, but not mRNA expression, is highest when ERα transcriptional activity is low.
Increased ErbB3 protein correlates with decreased ERα in luminal breast cancer cells
We used avidin-mediated pull-down of biotinylated cell surface proteins followed by western analysis to determine if ErbB3 levels were upregulated at the cell surface of fulvestrant-treated MCF7 breast cancer cells. After treatment for 24 hours, ErbB3 pull-down increased more than 3-fold in fulvestrant treated cells as compared to cells treated with DMSO (Fig. 2C ). ErbB3 was not pulled down by avidin beads in non-biotinylated cells, demonstrating the specificity of the assay. Thus ErbB3 protein presentation at the cell surface is upregulated in response to fulvestrant.
We further investigated fulvestrant-mediated ErbB3 up-regulation in four fulvestrant-treated luminal breast cancers cell lines, including lines with PIK3CA-H1047R activating mutations (T47D), PIK3CA-E545K activating mutations (MCF7 and MDA-MB-361), HER2 overexpression (MDA-MB-361) or with wild-type PIK3CA and HER2 (HCC1428).
Fulvestrant caused ErbB3 up-regulation in each of these cell lines within 24 hours (Fig. 2D ). Using cycloheximide (CHX) to block new protein synthesis, we found that ErbB3 protein levels decreased at time points following the addition of CHX to DMSO-treated cells, and were not detected after 120 minutes of CHX (Fig. 2D ). In contrast, fulvestrant decreased ERα expression but increased ErbB3 expression over what was seen in DMSO-treated cells.
In fulvestrant-treated HCC1428, MDA-MB-361 and T47D cells, ErbB3 remained abundant through 120 minutes after CHX treatment. In fulvestrant-treated MCF7 cells, however, ErbB3 diminished at a rate similar to what was seen in DMSO-treated cells. However, because baseline expression of ErbB3 was higher in fulvestrant-treated cells prior adding CHX, ErbB3 levels were still evident 120 minutes after CHX treatment. Thus, protein stabilization of ErbB3 may occur in response to fulvestrant in many luminal breast cancer cells, independently of PIK3CA mutation or HER2 amplification, but other mechanisms may also lead to ErbB3 protein up-regulation in response to fulvestrant.
LRIG1 decreases expression of ErbB3
To understand the molecular events that increase cell surface ErbB3 protein levels in fulvestrant-treated luminal breast cancer cells, we turned our attention to proteins involved in ErbB3 trafficking and degradation, including LRIG1 17 , Nrdp1 18 , 19 , and NEDD4 20 , which were over-expressed in 14% (33/235), 9% (22/235), and 8% (19/235) of Luminal A breast cancers, respectively. RPPA data from TCGA-curated luminal breast cancers did not reveal a report for total ErbB3 levels in tumors queried for LRIG1 or NRDP1 mRNA up-regulation, although total ErbB3 RPPA sores were reported upon query for NEDD4 up-regulation, revealing no association between ErbB3 protein levels and NEDD4 transcript expression (Supp. Fig. S2 ). However, the RPPA score for phospho-ErbB3 Y1289, a phospho-tyrosine induced by treatment of breast cancer cells with HRG ( Fig. 1A) or fulvestrant (Fig. 1B) , was reported in queries for LRIG1, Nrdp1, and NEDD4. Although no association was observed between P-ErbB3 Y1289 RPPA scores and either Nrdp1 or NEDD4, we found a statistically significant inverse relationship between LRIG1 and P-ErbB3 Y1289 (Fig. 3A) . Therefore, we focused further attention on the relationship between LRIG1 and ErbB3 in luminal breast cancer cells treated with and without fulvestrant.
We stably expressed a myc-epitope tagged LRIG1 construct 17 in MCF7, HCC1428, and T47D cells (Fig. 3B ). In addition to wild-type (WT) LRIG1, we also expressed a myctagged LRIG1 deletion mutant lacking the large ErbB3 interaction motif in the LRIG1 ectodomain (LRIG1 ΔEcto ) 21 , and an LRIG1 mutant lacking the short regulatory/inhibitory cytoplasmic domain (LRIG1 ΔCyto ) 21 . Cells were grown in 10% serum, and we assessed cell lysates by western analysis for ErbB3. We found that LRIG1 WT overexpression modestly decreased ErbB3 protein levels in each cell line as compared to cells expressing the empty vector pcDNA3, whereas expression of LRIG1 ΔEcto , which lacks the ErbB3 interaction motif, increased ErbB3 protein levels in each cell line tested. In contrast, ErbB3 was profoundly down-regulated in cells expressing LRIG1 ΔCyto , consistent with the reported increased ErbB-targeting activity of LRIG1 ΔCyto .
LRIG1 inhibits growth of luminal breast cancer cells through ErbB3 down-regulation
Previous studies demonstrate that LRIG1 suppresses growth of cancer cells 22 -25 . We used Kaplan Meier Plotter (kmplot.com) to examine patient survival in datasets of tamoxifentreated ER+ breast cancers (N = 665), bifurcating these tumors into those expressing high or low levels of LRIG1. The patients in this combined dataset were treated with tamoxifen.
Like fulvestrant, tamoxifen blocks the action of ERα, albeit through a distinct mechanism which warrants careful consideration in the context of the presented data. However, we used this publically available meta-analysis tool to identify potentially important information regarding an association between LRIG1 and response to endocrine-treated breast cancers. This approach identified a statistically significant decrease in disease-free survival for patients with tumors expressing lower LRIG1 levels (Fig. 4A) . In contrast, expression of NRDP1 or NEDD4 did not correlate with disease-free survival of tamoxifen-treated ER+ breast cancer patients (Supp. Fig. S3 ). These data suggest that LRIG1 expression and activity promotes a favorable outcome following tamoxifen treatment, and conversely that lower LRIG1 levels may predict a worse outcome for tamoxifen-treated patients.
To study this more directly, and to determine the role of ErbB3 in LRIG1-mediated growth inhibition, we measured the impact of exogenous LRIG1 expression in luminal breast cancer cells. (Fig. 4D) . Cell counting revealed that knock-down of Erbb3 reduced the growth of MCF7 cells expressing LRIG1 ΔEcto and MCF7 cells expressing the empty vector (Fig. 4E) . Although cells expressing LRIG1 WT displayed reduced growth as compared to cells expressing empty pcDNA3.1, knockdown of ErbB3 did not decrease growth of these cells further. These observations are consistent with the idea that the tumor suppressor LRIG1 decreases growth of luminal breast cancer cells through down-regulation of ErbB3.
To understand the consequences of LRIG1 depletion, we used two distinct siRNA sequences directed against human LRIG1 to knock-down LRIG1 expression. Western analysis confirmed knockdown of LRIG1 following transient transfection of sequences targeting LRIG1, but not control siRNA sequences (Fig. 4F) . ErbB3 levels were increased in MCF7 and HCC1428 cells upon LRIG1 knock-down, but were reduced in the presence of antibody A4. To assess the impact of LRIG1 knock-down on growth of luminal breast cancer cells, we seeded 2.0 X 10 6 MCF7 and HCC1428 cells 24 hours after siRNA transfection, then cultured cells for an additional 3 days in 10% serum, with and without antibody A4. Cell counting after 3 days revealed increased growth of cells transfected with LRIG1 siRNA as compared to cells transfected with control siRNA sequences (Fig. 4G) . Antibody A4 blocked the growth advantage conferred to MCF7 and HCC1428 cells by LRIG1 knockdown. Together, these data suggest that LRIG1 is a key mechanism restraining ErbB3-mediated growth in luminal breast cells.
Decreased LRIG1 levels in fulvestrant-treated luminal breast cancer cells
Previous reports demonstrate that estrogen-activated ERα transactivates the LRIG1 gene 22 .
Consistent with these findings, Luminal breast cancers with high ERα RPPA scores displayed significantly higher expression of LRIG1 mRNA ( Fig. 5A ; N = 235, P = 0.003). In contrast, ERα RPPA scores did not correlate with Nrdp1 or NEDD4 expression in luminal breast cancers. These data are consistent with the idea that LRIG1 is an ERα-activated factor in luminal breast cancers 22 . Therefore, we tested the hypothesis that ERα down-regulation in response to fulvestrant causes decreased expression of LRIG1. LRIG1 down-regulation was seen in MCF7, MDA-MB-361, HCC1428, and T47D cells cultured 24 h with fulvestrant as compared to LRIG1 levels seen in DMSO-treated cells (Fig. 5B) . Although down-regulation of ERα was nearly complete, LRIG1 down-regulation, as measured by western analysis, was partial in MCF7 and MDA-MB-361 cells, although LRIG1 was more substantially down-regulated in T47D and HCC1428 cells. We measured LRIG1 mRNA levels in MCF7, T47D, HCC1428, and MDA-MB-361 cells cultured 24 h in the presence or absence of fulvestrant, revealing a substantial reduction in LRIG1 mRNA levels in fulvestrant-treated cells (Fig. 5C ). Further, MCF7 and MDA-MB-361 xenografts from mice treated with fulvestrant for 7 days (N = 7) expressed a reduced level of LRIG1 transcripts as compared to control-treated tumors (Fig. 5D ). Conversely, MCF7 cells and T47D cells cultured in 10% charcoal-stripped serum and treated with 20 pM 17β-estradiol for 24 h upregulated LRIG1 protein levels while concurrently down-regulating ErbB3 protein levels (Fig. 5E ). This suggests that ERα positively regulates LRIG1 transcript levels in luminal breast cancer cells, although additional mechanisms may contribute to total LRIG1 protein levels.
Uncoupling LRIG1 from ERα sustains ErbB3 down-regulation in fulvestrant-treated breast cancer cells
To determine if exogenous expression of LRIG1 WT could maintain ErbB3 protein downregulation in fulvestrant-treated cells, we treated MCF7 cells expressing LRIG1 WT with fulvestrant for 24 h. Although LRIG1 levels were decreased in vector-control cells treated with fulvestrant, MCF7-LRIG1 WT cells maintained high LRIG1 expression levels following fulvestrant treatment (Fig. 6A) . Importantly, ErbB3 levels, which were elevated in fulvestrant-treated MCF7-pcDNA3 cells, remained low in fulvestrant-treated MCF7-LRIG1 WT cells. We also used biotinylation of cell surface proteins to demonstrate that fulvestrant-mediated up-regulation of cell surface ErbB3 is blocked in in cells expressing LRIG1WT as compared to MCF7-pcDNA3 cells (Fig. 6B) . Because LRIG1 inhibits growth of luminal breast cancer cells, and fulvestrant decreases expression of LRIG1, we wanted to test the hypothesis that LRIG1 down-regulation in response to fulvestrant results in a growth advantage that partially masks the tumor cell growth inhibition that could be achieved by fulvestrant. We tested this hypothesis in fulvestrant-treated MCF7 cells. Fulvestrant decreased the growth of MCF7-pcDNA3 cells over 7 days (Fig. 6C) . However, fulvestrantmediated growth inhibition was significantly greater in MCF7-LRIG WT cells and MCF7-LRIG ΔCyto cells as compared to MCF7-pcDNA3.1 cells. In contrast, MCF7-LRIG1 ΔEcto cells were relatively resistant to the growth inhibitory effects of fulvestrant, indicating that the ectodomain of LRIG1 is necessary for LRIG1-mediated growth inhibition. These data suggest that sustained expression of LRIG1 improves the response of luminal breast cancer cells to fulvestrant, and conversely that loss of ERα-dependent LRIG1 expression weakens tumor growth inhibition in response to fulvestrant. Western analysis confirmed continued up-regulation of ErbB3 at 7 days of fulvestrant treatment in MCF7 cells expressing pcDNA3 (Fig. 6D) . Taken together, these data suggest that ERα drives expression of the growth inhibitory protein LRIG1, a protein necessary for ErbB3 down-regulation (Fig. 6C) . Upon loss of ERα and hence loss of LRIG1, ErbB3 levels accumulate at the cell surface, contributing to growth in fulvestrant treated cells.
Discussion
We have shown previously that ErbB3 drives growth and survival of the normal luminal mammary epithelium through MAPK and PI3K pathways, respectively 26 . Similarly, luminal breast cancers also use ErbB3 to increase cell survival in a PI3K-dependent manner 27 , particularly in fulvestrant-treated cells 2 , 3 , making the combination of therapeutic ErbB3
antibodies with fulvestrant an attractive approach to treat luminal breast cancers. (Fig. 2) , where it sustains cell growth. These data are consistent with previous reports demonstrating that estrogen-activated ERα controls expression of LRIG1, such that estrogen deprivation or ERα targeting reduce expression of LRIG1 in luminal breast cancer cells 22 . These findings explain the relationships shown here between ErbB3 protein (but not mRNA), ERα protein, and LRIG1 mRNA in luminal breast cancers.
Importantly, decreased LRIG1 transcript levels correlated with decreased disease-free survival in tamoxifen-treated luminal breast cancers (Fig. 5) . Because LRIG1 negatively regulates cell surface levels of ErbB family RTKs, it is possible that increased signaling through ErbB family RTKs contributes to the worse outcome for those luminal breast tumors with low LRIG1. The ErbB RTK family is comprised of four members, including epidermal growth factor receptor (EGFR), ErbB2, ErbB3 and ErbB4 1 , 30 . Although our studies focus on
ErbB3, previous studies demonstrate that enforced over-expression of EGFR, ErbB2, or certain ErbB4 splice variants increases cell growth and survival in tamoxifen-treated luminal breast cancer cells 3 -5 , 8 , 31 . While we have not ruled out the potential roles of EGFR, ErbB2, and ErbB4 in regulating the response of luminal breast tumors to fulvestrant, we found that antibody-based ErbB3 targeting neutralized ErbB3 up-regulation in fulvestrant-treated cells, resulting in profound growth inhibition. Blockade of post-therapeutic ErbB3 up-regulation by antibody A4 has been reported in Raf/Mek inhibitor-treated melanomas 15 , 32 , and EGFR inhibitor treated non-small cell lung cancers 33 . Moreover, we found that the ErbB3 antibody blocked cell growth caused by LRIG1 knock-down or dominant-negative LRIG1 ΔEcto expression.
In summary, we have shown herein that the ERα-regulated gene LRIG1 suppresses cell surface ErbB3 expression and signaling in luminal breast cancers, such that ErbB3 rapidly accumulates on the cell membrane following treatment with fulvestrant. Previous studies demonstrate the profound impact of ErbB3 up-regulation on PI3K-Akt-mTOR signaling in fulvestrant-treated breast cancers 2 , 3 . Although mTOR inhibitors are approved in combination with endocrine therapy to prevent the consequences of this feedback inhibition 34 , mTOR inhibitors are often poorly tolerated. Because ErbB3-targeting antibodies block resurgent signaling through the PI3K-Akt pathway in fulvestrant-treated cells 2 , these data suggest that ErbB3 antibodies might be a therapeutic alternative for use in combination with endocrine inhibitors.
Materials and Methods
Cell Culture
All human breast cancer cell lines (MCF7, T47D, HCC1428, MDA-MB-361) were obtained from American Tissue Type Collection (Rockville, MD) and were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologics) except where indicated as serum-free. Fulvestrant (1 μM) (SigmaAldrich) and Heregulin-1β epidermal growth factor-like domain (2 ng/ml, R&D Systems), and the humanized ErbB3 monoclonal antibody A4 14 , 15 were used where indicated. Colony assays were seeded in 6-well dishes (10 5 cells/dish), and cultured 14d in DMEM/10% FBS. Cells were fixed in formalin, stained with crystal violet, imaged on a flatbed scanner, converted to binary images, and quantified using Image J software. Cells (1 X 10 5 ) were transfected using Xfect Reagent (Clontech) according to manufacturer's directions with 2 μg plasmid DNA: pcDNA3.1 (Life Technologies/InVitrogen), pcDNA3.1-LRIG1, pcDNA3.1-LRIG1-ΔEcto, and pcDNA3.1-LRIG1-ΔCyto 21 , 22 . LRIG1 siRNA and non-specific siRNA sequences were purchased (Dharmacon) and used for transfection of cells with Dharmafect (Dharmacon) according to manufacturer's directions.
Western blotting and immunoprecipitation
Cells were homogenized in ice-cold lysis buffer [50 mM Tris pH 7.4, 100 mM NaF, 120 mM NaCl, 0.5% NP-40, 100 μM Na 3 VO 4 , 1X protease inhibitor cocktail (Roche)]. 1 mg lysates were used for immunorecipitation (IP) with ErbB3 (Santa Cruz Biotechnologies, C-17) or 9E10 (Sigma-Aldrich) at 1:200 (v/v) for 2 h, then pulled down with Protein A/G+ agarose (Santa Cruz Biotechnologies) at 1:20. IPs or cell lyates (20 μg) were denatured in reducing sample buffer, resolved by 4-12% SDS-PAGE (Novex, Life Technologies), and transferred to nitrocellulose membranes (iBlot, Life Technologies). Membranes were blocked and probed with antibody as previously described 26 using the following antibodies: ErbB3
(C-17, Santa Cruz Biotechnology; 1:1000); Y1289 P-ErbB3 (Cell Signaling; 1:1000); 9E10 (Sigma-Aldrich; 1:2000); LRIG1 (Sigma-Aldrich; 1:500), α-actin (Sigma-Aldrich; 1:20,000).
Biotinylation of cell surface proteins
Cells were cultured to 80-90% confluence, then incubated 30 min at 4°C with EZ-Link Sulfo-NHS-SS-Biotin in the Pierce Cell Surface Protein Isolation Kit (Thermo Scientific) according to manufacturer's specifications. Cells were lysed in Pierce Lysis Buffer (Thermo Scientific) supplemented with protease inhibitor cocktail (Roche), sonicated five times at low power on ice for 1 second each, and clarified by centrifugation. Cells were collected, washed, and eluted with dithiothreitol using NeutrAvidin Agarose beads provided with the Pierce Cell Surface Protein Isolation Kit (Thermo Scientific) according manufacturer's directions. Eluates were analyzed by western analysis.
Human breast tumor gene expression analysis
The Cancer Genome Atlas 35 Invasive Breast Cancer dataset was clustered according to PAM50 subtypes and corresponding data on ERBB3, LRIG1, NEDD4, and NRDP1 mRNA, patient survival, and ErbB3, ErbB3 PY1289, ESR1, and ESR1 P-S118 were analyzed using publically available software on the cBio Portal website 36 . Meta-analysis of expression array datasets of tamoxifen-treated Luminal A breast cancers were assessed for correlations between disease-free survival and expression of LRIG1 (211596_s_at), NRDP1 (201961_s_at), and NEDD4 (213012_at) using KmPlotter (KmPlot.com).
RNA extraction and quantitative reverse transcription-polymerase chain reaction (RT-PCR)
Using RNeasy (Qiagen), total RNA was harvested from cell lysates passed through a QiaShredder column (Qiagen) or from flash-frozen tumors homogenized using a tissue lyser. Total RNA was quantified and 2 ug RNA was used to synthesize cDNA (High Capacity cDNA Reverse Transcription kit -Applied Biosystems). Quantitative RT PCR was performed on a BioRad iCycler iQ5 machine using the following primer sequences:
Human LRIG1 F: 5′-TAA CTC GAG AAC CCA CTG CTT ACT-3′
Human LRIG1 R: 5′-CTA GAA GGC ACA CTC GAG GCT GAT-3′
Xenograft experiments
Estrogen pellets (14 d extended release, 0.17 mg β estradiol, Innovative Research of America) were implanted subcutaneouly into 3-4 week old female Balb/C athymic nude mice (Jackson Laboratories). Right and left inguinal mammary fatpads were injected with 10 6 MCF7 or MDA-MB-361 in 100 μl growth factor reduced Matrigel. Tumors were measured with calipers twice weekly. Tumor-bearing mice were randomized into treatment arms to receive fulvestrant (Novartis) delivered once weekly by intramuscular injection. All animal experimentation was performed in AAALAC approved facilities at Vanderbilt University Medical Center. All animal use protocols were reviewed and approved prior to experimentation by the Institutional Animal Care and Use Committee at Vanderbilt University, Nashville, TN.
Statistics Overview
To assess statistical significance in experiments directly comparing an experimental group to a control group, Student's unpaired, two-tail T-test was used. P < 0.05 was considered significantly different from the null hypothesis. 
